ClinicalTrials.gg
RecruitingNCT06364631CARE1Updated Jan 16, 2025

CARE1 Pragmatic Clinical Trial

A Phase 3 interventional study of Nivolumab and Ipilimumab in Metastatic Kidney Cancer and Metastatic Kidney Carcinoma, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 46 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-16.

Primary conditionCarcinoma, Renal CellRegistry: Kidney NeoplasmsReclassifiedWhy we changed it
Registry
Kidney Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Renal Cell
Why
  1. The study's title name Carcinoma, Renal Cell, a narrower term within Kidney Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 3, Interventional, and Treatment

How we know · 13 judgments

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies testing nivolumab in Carcinoma, Renal Cell — 9 open to participants now, 23 under way, 3 of them phase 3. Nivolumab · Carcinoma, Renal Cell.

Planned enrollment
3rd of 64
1,250 · median 52
Started
2024
with 4 others
Phase 3
8 of 64
1 open now
Primary completion
2032-05
later than 22 of 22 live
Registered
59th of 64
by date
Lead sponsor
2 of 64
Gustave Roussy, Cancer Campus, Grand Paris

Among the 64 studies testing nivolumab in Carcinoma, Renal Cell, this one is the 3rd largest by planned enrollment, is one of 5 that started in 2024, is one of 8 in phase 3, reaches primary completion later than 22 of the 22 other live ones, and was the 59th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

9 of the 64 studies testing nivolumab in Carcinoma, Renal Cell are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing nivolumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

Systemic therapy for renal cell carcinoma (RCC) relies on 2 classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI), targeting either PD1/PDL1 axis or CTLA4. Combination therapy is SOC for clear cell RCC in all guidelines with either ICI-ICI or ICI-VEGFR TKI. However, no head-to-head comparison have been performed between the 2 approaches and patients are treated based on physician decision without clinical /biomarker factors to guide treatment selection. PDL1 staining is, to date, the biomarker that has demonstrated its ability to enrich for overall survival benefit favoring ICI-ICI strategy in PDL1(+) and ICI-VEGFR TKI in PDL1(-) patients.

Study design has been developed to demonstrate that ICI-ICI is superior to ICI-VEGFR TKI in prolonging Overall Survival (OS) for PDL1(+) patients and to demonstrate that ICI-VEGFR TKI is superior to ICI-ICI in prolonging Progression Free Survival (PFS) and OS for PDL1(-) patients.

Read the detailed description

In 2020, there were an estimated 431 288 new cases of kidney cancer (Renal Cell Carcinoma, RCC) globally with 138 611 cases in Europe, leading to 179 368 deaths worldwide, including 54 054 deaths in Europe (source: IARC/Globocan). To define high priority topics in academic research and launch dedicated trials, European RCC academic physicians have gathered into a European initiative - the CARE group.

Systemic therapy for RCC relies on two classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI), targeting either PD-1/PD-L1 axis or CTLA-4. Combination therapy is standard of care (SOC) for clear cell RCC in all guidelines with either ICI-ICI or ICI-VEGFR TKI. However, no head-to-head comparison have been performed between the two approaches and patients are treated based on physician decision without clinical or biomarker factors to guide treatment selection. PD-L1 staining is, to date, the biomarker that has demonstrated its ability to enrich for overall survival benefit favoring ICI-ICI strategy in PD-L1(+) and ICI-VEGFR TKI in PD-L1(-) patients.

CARE1 PCT is a prospective randomize phase III study, in first line setting for patients with metastatic clear cell RCC comparing ICI-ICI vs ICI-VEGFR TKI approaches stratified on PD-L1 by local determination. Primary endpoint is overall survival (OS). The trial will enroll 1250 patients over 4 years across eight European countries (France, Spain, Netherlands, Czech Republic, Austria, Germany, Italy, UK) that are part of the CARE consortium. Study Sponsor is Gustave Roussy institute within the GETUG network for France, co-sponsor is developed through main academic networks (eg. SOGUG in Spain) and main institutions across Europe (eg. Cancer Core Europe - CCE). Study design has been develop to demonstrate that ICI-ICI is superior to ICI-VEGFR TKI in prolonging OS for PD-L1(+) patients and that ICI-VEGFR TKI is superior to ICI-ICI in prolonging OS for PD-L1(-) patients. CARE1 PCT has been designed and will be conducted with patient advocacy group representatives (ARTuR and IKCC) input.

CARE1 is an academic phase III study designed to define the optimal combination using a pragmatic routinely implementable biomarker. Therefore, CARE1 will inform practice and has the potential to change treatment guidelines. Taken all together, CARE1 is a unique opportunity to build a large-scale platform to define new biomarker based therapy guidelines as well as to investigate quality of life, patient reported outcome and Health-Economic in front line setting, as well as pathological and blood biobank collection for further translational work. This action is part of the Cancer Mission cluster of projects on 'Diagnosis and treatment'.

03

Conditions studied

  • Metastatic Kidney Cancer
  • Metastatic Kidney Carcinoma

Browse trials for

Keywords

  • METASTATIC KIDNEY CANCER
  • METASTATIC KIDNEY CARCINOMA
  • PRAGMATIC CLINICAL TRIAL
  • PDL1
04

In context

Carcinoma, Renal Cell Reclassified

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

This study's planned enrollment of 1,250 is above the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.

Browse Carcinoma, Renal Cell studies →

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 245 studies on the registry; 66 are open to participants now.

Compared within Carcinoma, Renal Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed (AJCC Stage IV) renal cell carcinoma with a clear-cell component.
  2. Intermediate- or poor-risk mRCC as defined by IMDC classification.
  3. Adult male or female patients (≥ 18 years of age at inclusion).
  4. Performance Status (KPS) ≥70%.
  5. Adequate organ and marrow function, according to investigator assessment and

    1. (ANC) ≥ 1000/μL (≥ 1.5 GI/L)
    2. ≥ 100,000/μL (≥ 100 GI/L)
    3. ≥ 8 g/dL (≥ 80 g/L)
    4. (ALT) and aspartate aminotransferase (AST) ≤ 5 x .
    5. Calculated ≥ 30 mL/min (≥ 0.67 mL/sec) using the CKD- EPI equation
  6. Patient should understand, sign, and date the written form prior to any protocol-specific procedures performed.
  7. Patient should be able and willing to comply with study visits and procedures as per protocol
  8. Patients must be affiliated to a social security system or beneficiary of the same
  9. Female patients must either be of non- or must have a negative serum pregnancy test within 14 days prior to the administration of study drug. women must have agreed to use one barrier method of , such as condom, plus an additional highly effective method of contraception during treatment on this trial and for up to 5 months after the last dose of study treatment.
  10. Fertile men with a female partner of childbearing potential must agree to use one barrier method of contraception, such as condom, during treatment on this trial and for up to 4 months after the last dose of treatment. Their women of childbearing potential partner must agree to use a highly effective method of contraception during the same period.
  11. Female subjects of childbearing potential must not be pregnant at screening.

Exclusion criteria

Exclusion Criteria:

  1. Prior systemic anticancer therapy for mRCC including agents. Note: One prior systemic therapy is allowed for completely resected RCC and if recurrence occurred at least 6 months after the last dose of adjuvant therapy.
  2. Uncontrolled (adequately treated with radiotherapy and/or radiosurgery prior to randomization are eligible). Subjects who are neurologically symptomatic as a result of their CNS metastasis or are receiving systemic treatment (prednisone equivalent > 10 mg/day) at the planned time of randomization are not eligible.
  3. Concomitant oral anti-vitamin K anticoagulation. An exception is the use of LMWH or direct oral anticoagulants (DOAC), if considered safe by investigator assessment.
  4. The subject has uncontrolled, significant intercurrent or recent illness such as the following conditions:

    a. Cardiovascular disorders:

    i. Congestive heart failure (CHF) class III or IV as defined by the , unstable angina pectoris, myocardial infarction, serious cardiac arrhythmias (e.g., ventricular flutter, ventricular fibrillation, Torsades de pointes).

    ii. Uncontrolled hypertension despite optimal antihypertensive treatment.

    iii. Stroke, or other symptomatic ischemic event or severe thromboembolic event (e.g., symptomatic pulmonary embolism [PE], incidental PE is acceptable if deemed safe by the investigator) within 3 months before randomization.

    b. Active GI bleeding or symptomatic Gastrointestinal (GI) tract obstruction

    c. bleeding including uncontrolled hematuria, hematemesis, or hemoptysis

    d. disease that has been symptomatic or required systemic treatment within the past two years from the date of randomization.

    Note: Patients with a history of Crohn's disease or ulcerative colitis are always excluded

    e. Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization.

    Note: Inhaled, intranasal, intra-articular, or topical steroids are permitted. Adrenal replacement steroid doses > 10 mg daily prednisone equivalent are permitted. Transient short-term use of systemic corticosteroids for allergic conditions (e.g., contrast allergy) is also allowed.

    f. Active infection requiring systemic treatment.

    g. Major surgery (e.g., nephrectomy, GI surgery, removal of brain metastasis) within 4 weeks prior to randomization or serious non-healing wound/ulcer/bone fracture.

  5. Pregnant or breastfeeding females.
  6. Any other active at time of randomization or diagnosis of another malignancy within 3 years prior to randomization that requires active treatment, except for locally curable cancers that have been apparently cured.
  7. to any of the active substances or to any of the administered during the study
  8. Use of within 28 days before randomization
  9. Persons deprived of their freedom or under guardianship, or for whom it would be impossible to undergo the medical follow-up required by the trial, for geographic, social or psychological reasons.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,250 participants (estimated)

Study arms

  • Other
    Arm A: ICI - ICI Combination

    Nivolumab (3 mg/kg infusion, every 3 weeks) x 4 doses + ipilimumab (1 mg/kg infusion, every 3 weeks) x 4 doses. At the end of the 4 injections carried out 21 days apart and in the absence of limiting side effects or progression justifying the cessation of the treatment according to the investigating doctor, maintenance treatment with nivolumab will be continued, at a rate of one injection every 2 weeks at a dose of 240 mg or every 4 weeks at a dose of 480 mg depending on the choice of the investigating doctor. Nivolumab will be administered for a maximum of 2 years. Patients are required to receive all four doses of NIVO+IPI before beginning NIVO monotherapy except for ipilimumab-induced toxicity compatible with nivolumab maintenance.

    Drug: Nivolumab · Drug: Ipilimumab

  • Other
    Arm B: VEGFR-TKI- ICI arm (axitinib + pembrolizumab)

    Investigator's choice between: * Axitinib (5 mg oral twice a day) + pembrolizumab (200 mg flat IV every 3 weeks or 400 mg flat IV every 6 weeks). * Cabozantinib (40 mg oral, once a day away from meals) + nivolumab infusion (480 mg flat dose every 4 weeks) * Lenvatinib (20 mg oral, once a day) + pembrolizumab (200 mg flat IV every 3 weeks or 400 mg flat IV every 6 weeks)

    Drug: Nivolumab · Drug: Pembrolizumab · Drug: Cabozantinib · Drug: Axitinib · Drug: Lenvatinib

Interventions

  • Briefly, nivolumab is administered as an approximately 30-minute (240mg every 2 weeks) or 60-minute (480mg every 4 weeks) IV infusion. Nivolumab is to be administered first. The nivolumab infusion must be promptly followed by a saline flush to clear the line of nivolumab before starting the ipilimumab infusion.

    Also known as: OPDIVO

  • The second infusion will always be ipilimumab and will start at least 30 minutes after completion of the nivolumab infusion. Ipilimumab is to be administered as an approximately 30-minute IV infusion. When administered together, nivolumab and ipilimumab will be administered on Day 1 of each 21-day cycle.

    Also known as: YERVOY

  • Pembrolizumab is to be administered as an approximately 30-minute IV infusion.

    Also known as: KEYTRUDA

  • Cabozantinib is a medication that is taken orally every day, once a day away from meals at the initial dose of 40 mg/day.

    Also known as: CABOMETYX

  • Axitinib is a medication that is taken orally every day, 2 times a day continuously, at the starting dose of 5mg x2/day.

    Also known as: INLYTA

  • Lenvatinib is a medication that is taken orally every day, once a day at the initial dose of 20mg/day.

    Also known as: LENVIMA

07

What researchers measure

Primary outcomes

  1. Overall Survival (OS).

    From randomization to time of death

    Time frame: At end of study, 97 months

Secondary outcomes

  1. Progression-free survival according to RECIST 1.1

    From randomization to progression, also a primary outcome for PDL1(-) population.

    Time frame: At end of study, 97 months

  2. Objective Response Rate (ORR) according to RECIST 1.1

    ORR (estimand 3) is defined as the percentage of randomised participants (ITT set) who achieve a best response of complete response (CR) or partial response (PR) over the treatment observation period based on Investigators assessments.

    Time frame: At end of treatment, 60 months

  3. Quality of Life via questionnaire EQ-5D-5L

    Patient's response to the Quality of Life questionnaire EQ-5D-5L.

    Time frame: Baseline, Month 3, Month 6, Month 9, Month 12

  4. Quality of Life via questionnaire NNCCN/FACT Kidney Cancer Symptom Index (NFKSI)

    Patient's response to the Quality of Life questionnaire NFKSI19.

    Time frame: Baseline, Month 3, Month 6, Month 9, Month 12

  5. Quality of Life via questionnaire Kidney Symptom Index (KSI)

    Patient's response to the Quality of Life questionnaire KSI.

    Time frame: Baseline, Month 3, Month 6, Month 9, Month 12

  6. Duration of Treatment

    Duration of protocolar treatment administration.

    Time frame: At end of treatment, 60 months

  7. Time to treatment discontinuation (TTD)

    TTD is defined as the time from the date of treatment initiation to the date of last treatment dose.

    Time frame: At end of treatment, 60 months

  8. Treatment-free survival (TFS)

    TFS is defined as the date from protocol therapy cessation (whatever the reason) to the date of subsequent systemic therapy initiation or death.

    Time frame: At end of study, 97 months

  9. Time to subsequent systemic anticancer therapy (TTSST)

    TTSST is defined the time from the date of randomization to the date of next subsequent systemic therapy.

    Time frame: At end of study, 97 months

  10. Incidence of AE's

    Incidence of AEs will be summarized by system organ class and preferred term according to MedDRA coding, and will be presented by treatment groups and overall.

    Time frame: At end of treatment, 60 months

  11. Health Economic evaluation: healthcare costs [France & Netherlands only]

    The cost difference between arms in each patient subgroup (comparison of healthcare costs)

    Time frame: At end of study, 97 months

  12. Health Economic evaluation: cost-utility [France & Netherlands only]

    The incremental cost per QALY and the incremental net monetary benefit in each patient subgroup (cost-utility analysis).

    Time frame: At end of study, 97 months

08

Study locations

33 of 46 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for May 2032, 96 months after the start.

Of 61 phase 3 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 89. This study's planned 96 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2024
First posted
Apr 15, 2024
StartActual
Apr 12, 2024
Primary completionEst.
May 5, 2032
CompletionEst.
May 5, 2032
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06364631
Collaborators
European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London
Responsible party
Sponsor
First posted
Apr 15, 2024
Start date
Apr 12, 2024
Primary completion
May 5, 2032 (estimated)
Completion
May 5, 2032 (estimated)
Last update
Jan 16, 2025

Study contacts

Laurence ALBIGES, MD, PhD
Contact
laurence.albiges@gustaveroussy.fr
+33 (0)1 42 11 66 90
Maia CLAVEAU
Contact
Maia.CLAVEAU@gustaveroussy.fr
+33 (0)1 42 11 53 49
Laurence ALBIGES, MD, PhD
study chair · Gustave Roussy, Cancer Campus, Grand Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab · Pembrolizumab · Cabozantinib · Axitinib · Lenvatinib

Start the discussion